aT Center
10th Floor 27 Gangnamdae-ro Seocho-gu
Seoul
South Korea
82 2 501 1084
https://www.enzychem.com
Sector(es):
Sector:
Empleados a tiempo completo:
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Ki-Young Sohn | Chairman & Chief Executive Officer | N/A | N/A | N/A |
Dr. G. Alexander Fleming M.D., Ph.D. | Member of Corporate Advisory Committee & CTO | N/A | N/A | N/A |
Mr. Do-Young Lee | Chief Scientific Officer & Member of the Board of Directors | N/A | N/A | N/A |
Myung-Hwan Kim M.D., Ph.D. | CMO & Director | N/A | N/A | N/A |
Dr. Jeff Clark | Chief Licensing Officer | N/A | N/A | N/A |
Mr. John Choi | Executive Director | N/A | N/A | N/A |
Jae-Yong Lee | VP & Executive Director | N/A | N/A | N/A |
Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea.
El ISS Governance QualityScore de Enzychem Lifesciences Corporation, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.